Background: The inherited thrombophilic mutations of the factor V gene (FVG1691A Leiden-FVL), prothrombin gene (PTG20210A), and the methylenetetrahydrofolate reductase gene C677T (MTHFR C677T) are risk factors for thromboembolic events and are related to the pathogenesis of vascular diseases. Objectives: The main objective of this study was to explore the role of these factors in the pathogenesis of chronic kidney disease (CKD) and survival of patients with CKD-5 receiving haemodialysis. Methods: A cohort of 395 patients with CKD-5 on haemodialysis, from 6 dialysis units in Crete, Greece were recruited based on their medical records and were followed for 5 years. We collected data on CKD-5 aetiology, thrombophilic gene expression, vascular access thrombosis, time of death, and causes of death. Results: The mutated genes just as prevalent in patients with CKD-5 as they were in a control group with no renal disease (p > 0.05). FVL heterozygosity was significantly more prevalent (11.4 vs. 5.7%; p = 0.036) in patients presented with CKD of unknown aetiology, compared to CKD secondary to known aetiologies. The survival of patients with CKD-5 receiving haemodialysis was not affected by the presence of any thrombophilic mutation. This held true for the whole cohort and for the cohort that included only lethal vascular events. Most patients with MTHFR C677T heterozygosity, and all patients with MTHFR C677T homozygosity, died from vascular events during the follow-up period. Conclusion: The FVL mutation may act as a risk factor for CKD. This study increases our understanding of molecular mechanisms in the pathogenesis of CKD of unknown aetiology. Τhe presence of thrombophilic mutations did not affect the overall survival of patients with CKD-5. This finding probably reflects the effect of medical care on patient outcomes.

1.
Nicolaides
AN
,
Breddin
HK
,
Carpenter
P
,
Coccheri
S
,
Conard
J
,
DeStefano
V
, et al
Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence
.
Int Angiol
.
2005 Mar
;
24
(
1)
:
1
26
.
2.
Murin
S
,
Marelich
GP
,
Arroliga
AC
,
Matthay
RA
.
Hereditary thrombophilia and venous thromboembolism. Diagnosis and management of heritable thrombophilias
.
Am J Respir Crit Care Med
.
1998
;
158
(
5
):
1369
73
.
3.
Antoniadi
T
,
Hatzis
T
,
Kroupis
C
,
Economou-Petersen
E
,
Petersen
MB
.
Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors
.
Am J Hematol
.
1999
;
61
(
4
):
265
7
. .
4.
Thorelli
E
,
Kaufman
RJ
,
Dahlbäck
B
.
Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V
.
Blood
.
1999
;
93
(
8
):
2552
8
. .
5.
Castoldi
E
,
Brugge
JM
,
Nicolaes
GA
,
Girelli
D
,
Tans
G
,
Rosing
J
.
Impaired APC cofactor activity of factor V plays a major role inthe APC resistance associated with the factor V Leiden (R506Q)and R2 (H1299R) mutations
.
Blood
.
2004
;
103
(
11
):
4173
9
.
6.
Carter
AM
,
Sachchithananthan
M
,
Stasinopoulos
S
,
Maurer
F
,
Medcalf
RL
.
Prothrombin G20210A is a bifunctional gene polymorphism
.
Thromb Haemost
.
2002
;
87
(
5
):
846
53
. .
7.
Gehring
NH
,
Frede
U
,
Neu-Yilik
G
,
Hundsdoerfer
P
,
Vetter
B
,
Hentze
MW
, et al
Increased efficiency of mRNA 3′ endformation: a new genetic mechanism contributing to hereditary thrombophilia
.
Nat Genet
.
2001
;
28
(
4
):
389
92
.
8.
Frosst
P
,
Blom
HJ
,
Milos
R
,
Goyette
P
,
Sheppard
CA
,
Matthews
RG
, et al
A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase
.
Nat Genet
.
1995
;
10
(
1
):
111
3
. .
9.
Ekim
M
,
Ekim
H
,
Yılmaz
YK
.
The prevalence of Factor V Leiden, prothrombin G20210A, MTHFR C677T and MTHFR A1298C mutations in healthy Turkish population
.
Hippokratia
.
2015 Oct–Dec
;
19
(
4)
:
309
13
.
10.
Weisberg
I
,
Tran
P
,
Christensen
B
,
Sibani
S
,
Rozen
R
.
A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity
.
Mol Genet Metab
.
1998
;
64
(
3
):
169
72
. .
11.
MLiu
F
,
Silva Dalone
MV
,
Seetharaman
K
.
MTHFR A1298C and C677T Polymorphisms are associated with increased risk of venous thrombo embolism: a retrospective chart review study
.
Acta Haematol
.
2017
;
138
:
208
21
.
12.
Kohara
K
,
Fujisawa
M
,
Ando
F
,
Tabara
Y
,
Niino
N
,
Miki
T
, et al
MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the Japanese general population: the NILS-LSA Study Stroke
.
2003
;
34
(
5
):
1130
5
13.
Den Heijer
M
,
Koster
T
,
Blom
HJ
,
Bos
GM
,
Briet
E
,
Reitsma
PH
, et al
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
.
N Engl J Med
.
1996
;
334
(
12
):
759
62
. .
14.
Bezemer
ID
,
Doggen
CJ
,
Vos
HL
,
Rosendaal
FR
.
No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study
.
Arch Intern Med
.
2007
;
167
(
5
):
497
501
.
15.
Rosendaal
FR
,
Koster
T
,
Vandenbroucke
JP
,
Reitsma
PH
.
High riskof thrombosis in patients homozygous for factor V Leiden(activated protein C resistance) Blood
.
1995
;
85
(
6
):
1504
8
.
16.
Margaglione
M
,
Brancaccio
V
,
Giuliani
N
,
D'Andrea
G
,
Cappucci
G
,
Iannaccone
L
, et al
Increased risk for venous thrombosis in carriers of the prothrombin G-->A20210 gene variant
.
Ann Intern Med
.
1998
;
129
(
2
):
89
93
. .
17.
Boekholdt
SM
,
Kramer
MH
.
Arterial thrombosis and the role of thrombophilia
.
Semin Thromb Hemost
.
2007
;
33
(
6
):
588
96
. .
18.
Kim
RJ
,
Becker
RC
.
Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolatereductase C677T mutations and events of the arterial circulatory system: a meta analysis of published studies
.
Am Heart J
.
2003
;
146
(
6
):
948
57
.
19.
Johannes FE Mann, MD Karl F Hilgers, MD Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis. Up to Date 2018
.
20.
Caetano
ER
,
Zatz
R
,
Saldanha
LB
,
Praxedes
JN
.
Hypertensive nephrosclerosis as a relevant cause of chronic renal failure
.
Hypertension
.
2001
;
38
(
2
):
171
6
. .
21.
Zucchelli
P
,
Zuccalà
A
.
Primary hypertension: how does it cause renal failure?
Nephrol Dial Transplant
.
1994
;
9
(
3
):
223
5
.
22.
Campese
VM
,
Karubian
F
.
Salt sensitivity in hypertension: implications for the kidney
.
J Am Soc Nephrol
.
1991
;
2
(
2 Suppl 1
):
S53
61
.
23.
Zucchelli
P
,
Zuccalà
A
.
The diagnostic dilemma of hypertensive nephrosclerosis: the nephrologist,s view
.
Am J Kidney Dis
.
1993
;
21
(
5 Suppl 2
):
87
91
. .
24.
Goforth
RL
,
Rennke
H
,
Sethi
S
.
Renal vascular sclerosis is associated with inherited thrombophilias
.
Kidney Int
.
Int2006
;
70
(
4
):
743
50
. .
25.
Kozlovskaia
NL
,
Bobrova
LA
,
Shkarupo
VV
,
Varshavskiĭ
VA
,
Miroshnichenko
NG
.
[Clinicomorphological characteristics of renal disorders in patients with genetic thrombophilia]
.
Ter Arkh
.
2009
;
81
(
8
):
30
6
.
26.
Koupepidou
P
,
Deltas
C
,
Christofides
TC
,
Athanasiou
Y
,
Zouvani
I
,
Pierides
A
.
The MTHFR 677TT and 677CT/1298AC genotypes in Cypriot patients may be predisposing to hypertensive nephrosclerosis and chronic renal failure
.
Int Angiol
.
2005
;
24
(
3
):
287
94
.
27.
Tripathi
G
,
Sankhwar
SN
,
Sharma
RK
,
Baburaj
VP
,
Agrawal
S
.
Role of thrombotic risk factors in end-stage renal disease
.
Clin Appl Thromb Hemost
.
2010
;
16
(
2
):
132
40
. .
28.
Perez-Pujol
S
,
Aras
O
,
Escolar
G
.
Factor v leiden and inflammation
.
Thrombosis
.
2012
;
2012
:
594986
. .
29.
Madhusudhan
T
,
Kerlin
BA
,
Isermann
B
.
The emerging role of coagulation proteases in kidney disease
.
Nat Rev Nephrol
.
2016
;
12
(
2
):
94
109
. .
30.
Mailloux
L
,
Henrich
W
.
Patient survival and maintenance dialysis
.
UptoDate
.
2019
.
31.
Fung
MM
,
Salem
RM
,
Lipkowitz
MS
,
Bhatnagar
V
,
Pandey
B
,
Schork
NJ
, et al
AASK Study Investigators Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Studyof Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC)
.
Nephrol Dial Transplant
.
2012
;
27
(
1
):
197
205
.
32.
Tsimperidis
AG
,
Kapsoritakis
AN
,
Linardou
IA
,
Psychos
AK
,
Papageorgiou
AA
,
Vamvakopoulos
NC
, et al
The role of hypercoagulability in ischemic colitis
.
Scand J Gastroenterol
.
2015
;
50
(
7
):
848
55
. .
33.
Theodoropoulou
A
,
Sfiridaki
A
,
Oustamanolakis
P
,
Vardas
E
,
Livadiotaki
A
,
Boumpaki
A
, et al
Genetic risk factors in young patients with ischemic colitis
.
Clin Gastroenterol Hepatol
.
2008
;
6
(
8
):
907
11
. .
34.
Koutroubakis
IE
,
Sfiridaki
A
,
Theodoropoulou
A
,
Kouroumalis
EA
.
Role of acquired and hereditary thrombotic risk factors in colon ischemia of ambulatory patients
.
Gastroenterology
.
2001
;
121
(
3
):
561
5
. .
35.
Wai Keat Chin
B
,
Greenberg
D
,
Wilson
R
,
Meredith
C
.
A case of ischemic colitis associated with factor V Leiden mutation: successful treatment with anticoagulation
.
GIE
.
2007
;
66
(
2
):
416
8
.
36.
Pabinger
I
,
Vossen
CY
,
Lang
J
,
Conard
j
,
García-Dabrio
MC
,
Miesbach
W
, et al
Mortality and inherited thrombophilia: results from the European Prospective Cohort on Thrombophilia
.
J Thromb Haemost
.
2012
;
10
(
2
):
217
22
. .
37.
Reitter-Pfoertner
S
,
Waldhoer
T
,
Mayerhofer
M
,
Eigenbauer
E
,
Ay
C
,
Mannhalter
C
, et al
The influence of thrombophilia on the long-term survival of patients with a history of venous thromboembolism
.
Thromb Haemost
.
2013
;
109
(
1
):
79
84
. .
38.
Ocak
G
,
Drechsler
C
,
Vossen
CY
,
Vos
HL
,
Rosendaal
FR
,
Reitsma
PH
, et al
Single nucleotide variants in the protein C pathway and mortality in dialysis patients
.
PLoS One
.
2014
;
9
(
5
):
e97251
7
. .
39.
Schroijen
MA
,
Dekkers
OM
,
Grootendorst
DC
,
Noordzij
M
,
Romijn
JA
,
Krediet
RT
, et al
Survival in dialysis patients is not different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid condition
.
BMC Nephrol
.
2011
;
12
:
69
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.